The dengue virus is the cause of dengue fever, a disease that is prevalent in many regions around the world. Dengue fever is a significant public health concern, particularly in tropical and subtropical areas. The virus has four distinct serotypes and is transmitted to humans through the bites of infected Aedes mosquitoes, which can result in potentially fatal infections. There is currently no specific antiviral treatment for this disease; management mainly involves supportive care for those experiencing symptoms. Therefore, prevention is one of the most effective strategies for controlling this infection. The most effective measure for preventing the disease is vaccination. In recent years, substantial efforts have been made to develop a vaccine effective against all four serotypes of the virus. To date, only one vaccine has been approved, while several others are in phase II and III clinical trials to confirm their efficacy. The development of a dengue vaccine faces several challenges, such as the need for effectiveness against all serotypes, issues related to antibody-dependent enhancement, cross-reactive immune responses, and age-related efficacy limitations. This paper examines the key strategies for vaccine development and the latest advancements in creating an effective dengue vaccine.
Moghadasi et al. (Thu,) studied this question.